Zobrazeno 1 - 10
of 413
pro vyhledávání: '"Julia A. Johansen"'
Autor:
Lara Magni, Haoran Yu, Nynne M. Christensen, Mette H. Poulsen, Alexander Frueh, Ganga Deshar, Astrid Z. Johansen, Julia S. Johansen, Stephan A. Pless, Niklas R. Jørgensen, Ivana Novak
Publikováno v:
Cancer Cell International, Vol 24, Iss 1, Pp 1-16 (2024)
Abstract Background The purinergic P2X7 receptor (P2X7R) plays an important role in the crosstalk between pancreatic stellate cells (PSCs) and cancer cells, thus promoting progression of pancreatic ductal adenocarcinoma (PDAC). Single nucleotide poly
Externí odkaz:
https://doaj.org/article/fe7eeb715b5d4909a0fb35c22c90c785
Autor:
Marina Crespo-Bravo, Jeppe Thorlacius-Ussing, Neel I. Nissen, Rasmus S. Pedersen, Mogens K. Boisen, Maria Liljefors, Astrid Z. Johansen, Julia S. Johansen, Morten A. Karsdal, Nicholas Willumsen
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background Collagens are the major components of the extracellular matrix (ECM) and are known to contribute to tumor progression and metastasis. There are 28 different types of collagens each with unique functions in maintaining tissue struc
Externí odkaz:
https://doaj.org/article/8e62a07ff1ff43e4a58ac916255a431b
Autor:
Lasse Bøllehuus Hansen, Sandra Fugl Jakobsen, Egija Zole, Julie Boertmann Noer, Li Tai Fang, Sefa Alizadeh, Julia Sidenius Johansen, Marghoob Mohiyuddin, Birgitte Regenberg
Publikováno v:
Cancer Medicine, Vol 12, Iss 17, Pp 17679-17691 (2023)
Abstract Backgrounds Despite recent advances, many cancers are still detected too late for curative treatment. There is, therefore, a need for the development of new diagnostic methods and biomarkers. One approach may arise from the detection of extr
Externí odkaz:
https://doaj.org/article/ca8394e32a374f9c84d0a8c522769fba
Autor:
Louise Skau Rasmussen, Stine B. Winther, Inna M. Chen, Britta Weber, Lise Ventzel, Gabor Liposits, Julia Sidenius Johansen, Sönke Detlefsen, Ida Egendal, Susy Shim, Signe Christensen, Per Pfeiffer, Morten Ladekarl
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background According to current evidence, the best treatment for fit patients with non-resectable pancreatic cancer (PC) is combination chemotherapy, whereas frail patients are recommended gemcitabine (Gem) monotherapy. Randomized controlled
Externí odkaz:
https://doaj.org/article/9b0b9ded99b04bf2a4fe11a35852398d
Autor:
Jessica Xin Hjaltelin, Sif Ingibergsdóttir Novitski, Isabella Friis Jørgensen, Troels Siggaard, Siri Amalie Vulpius, David Westergaard, Julia Sidenius Johansen, Inna M Chen, Lars Juhl Jensen, Søren Brunak
Publikováno v:
eLife, Vol 12 (2023)
Pancreatic cancer is one of the deadliest cancer types with poor treatment options. Better detection of early symptoms and relevant disease correlations could improve pancreatic cancer prognosis. In this retrospective study, we used symptom and disea
Externí odkaz:
https://doaj.org/article/76e100e6cca04e0d8c162a01a2f6d0cc
Autor:
Alex N. Videmark, Ib J. Christensen, Claus L. Feltoft, Mette Villadsen, Frederikke H. Borg, Barbara M. Jørgensen, Stig E. Bojesen, Caroline Kistorp, Randi Ugleholdt, Julia S. Johansen
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 6675-6688 (2023)
Abstract Background and methods Inflammation is a hallmark of cancer and its progression. Plasma levels of C‐reactive protein (CRP), interleukin‐6 (IL‐6) and YKL‐40 reflect inflammation, and are elevated in patients with cancer. This study in
Externí odkaz:
https://doaj.org/article/62fc18b41ccd406eaeecc67cdcffc730
Autor:
Sidsel C. Lindgaard, Zsófia Sztupinszki, Emil Maag, Carsten P. Hansen, Inna M. Chen, Astrid Z. Johansen, Jane P. Hasselby, Stig E. Bojesen, Dorte Nielsen, Julia S. Johansen
Publikováno v:
Cancer Medicine, Vol 12, Iss 4, Pp 3972-3986 (2023)
Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death. Less than 20% of patients are diagnosed with resectable disease. Identifying truly resectable disease is challenging because 20%–40% of the pat
Externí odkaz:
https://doaj.org/article/fb52e57547d541348b9adfb96269d526
Autor:
Benjamin Emil Stubbe, Anders Christian Larsen, Poul Henning Madsen, Henrik Bygum Krarup, Inge Søkilde Pedersen, Søren Lundbye-Christensen, Carsten Palnæs Hansen, Jane Preuss Hasselby, Astrid Zedlitz Johansen, Ole Thorlacius-Ussing, Julia Sidenius Johansen, Stine Dam Henriksen
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionCurrent prognostic blood-based biomarkers for pancreatic adenocarcinoma (PDAC) are limited. Recently, promoter hypermethylation of SFRP1 (phSFRP1) has been linked to poor prognosis in patients with gemcitabine-treated stage IV PDAC. This
Externí odkaz:
https://doaj.org/article/f44347b6f1ea445e969725de09fab180
Autor:
Neel I. Nissen, Astrid Z. Johansen, Inna M. Chen, Christina Jensen, Emilie A. Madsen, Carsten P. Hansen, Jeppe Thorlacius-Ussing, Morten Karsdal, Julia S. Johansen, Hadi M. H. Diab, Lars N. Jørgensen, Nicholas Willumsen
Publikováno v:
Frontiers in Molecular Biosciences, Vol 10 (2023)
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is characterized by a pronounced fibrotic tumor microenvironment, which impairs treatment response. Type I and V collagens are responsible for the densely packed fibrils in the tumor fibrosis envi
Externí odkaz:
https://doaj.org/article/8f4be5d66b1d42658607a755ed58cc35
Autor:
Troels D. Christensen, Emil Maag, Ole Larsen, Claus L. Feltoft, Kaspar René Nielsen, Lars Henrik Jensen, Bonna Leerhøy, Carsten P. Hansen, Inna M. Chen, Dorte L. Nielsen, Julia S. Johansen
Publikováno v:
JHEP Reports, Vol 5, Iss 3, Pp 100648- (2023)
Background & Aims: Biliary tract cancer (BTC) is associated with a dismal prognosis, partly because it is typically diagnosed late, highlighting the need for diagnostic biomarkers. The purpose of this project was to identify and validate multiprotein
Externí odkaz:
https://doaj.org/article/51bf95d915174913b37fd8a23ae83013